Inventurus Knowledge Solutions Ltd

- The transcript does not mention any current or planned fundraising through debt or equity. - The transaction discussed involves $600 million of debt attributed to the acquisition of TruBridge. - This debt is expected to be serviced with strong interest coverage (nearly 5x) on the EBITDA generated pre-synergies. - The deal is expected to be instantly PAT and EPS accretive from closing without requiring additional equity or debt fundraising. - There is emphasis on operating cash flows and internal accruals to manage debt and interest costs. - No explicit commentary on future fundraising plans through equity or additional debt was provided during the call.

- There is a significant focus on modernizing the Electronic Health Record (EHR) system, aiming to move it to a true cloud-native, AI-first model. - Investment in addressing and overcoming technical debt related to the EHR platform is planned. - Development and launch of a proprietary small language model for acute Revenue Cycle Management (RCM) to leverage AI more effectively, reducing compute costs. - Enhancements in clinical documentation and patient engagement technologies, utilizing AI and patent-pending innovations. - Strategic investments to integrate and combine TruBridge and IKS systems over four years, aiming for operational transformation while maintaining customer and talent retention. - Continuous tech investments to build an integrated platform system of action coupled with a system of record for enhanced scalability and competitive moat creation.

- Expect significant growth from cross-selling Revenue Cycle Management (RCM) services into TruBridge's existing EHR customer base, an immediate low-hanging fruit opportunity valued around $450 million, expanding to about $600 million in the near term. - Expansion beyond the TruBridge install base into the broader $3.5 billion rural hospital RCM market, which is growing at 12-13% annually, provides additional revenue opportunities. - Planned modernization and transformation of TruBridge's EHR into a cloud-native, AI-first platform expected to unlock further penetration in 0-50 bed hospitals and growth into 50-200 bed hospitals. - Accelerate sales of TruCode, the coding assistance SaaS tool with a $650 million total addressable market (TAM), both within and outside the TruBridge base. - Long-term goal: tripling EBITDA to approximately INR 3,000 crores by FY30 with a 31% CAGR in EBITDA over 4 years, supported by operational and G&A synergies.

- The combined entity expects significant growth, targeting nearly INR 3,000 crores EBITDA by FY30, implying a 31% CAGR from Dec 2025 to Mar 2030. - Current EBITDA is about INR 1,000 crores with net debt around INR 300 crores. - Pro forma combined EBITDA margin expected to increase from 26% initially to early 30s within 2-3 years. - The transaction is instantly PAT and EPS accretive by approximately $5 million at close, even before synergies. - Synergies expected from G&A optimization, delivery transformation, and cross-selling opportunities, particularly in rural healthcare. - Growth drivers include expansion in the RCM market, modernization of EHR to AI-first cloud-native systems, and leveraging TruBridge’s customer base. - A 4-5 year integration and operational transformation timeline is anticipated to realize full synergy potential and growth. - The company aims to under-promise and over-deliver, using a 4-year True North as a strategic guide rather than precise guidance.

The transcript from the provided pages does not explicitly mention details regarding the current or expected order book or pending orders for IKS Health Limited or TruBridge. The discussion primarily focuses on: - Strategic rationale and integration plans post TruBridge acquisition. - Synergies expected from combining technology and market reach. - Operational transformation timelines (starting early Q3 post-close). - Focus on customer and talent retention to drive growth. - Financial considerations such as interest cost assumptions. - Market positioning and competitive landscape insights. - Growth outlook over a four-year timeline and beyond. No specific numeric data or commentary about order book or pending orders status is available in the provided pages.